Basecamp Research, working with Nvidia and NVentures investment, disclosed EDEN — an ‘‘evolutionary AI’’ family of models that the company says can design sequences for programmable insertion of large therapeutic DNA at precise genomic sites. The preprint and company statements claim EDEN was trained on roughly 9.7 trillion biological tokens from BaseData and that designs succeeded across more than 10,000 disease-relevant genome locations. Basecamp demonstrated in vitro integration of therapeutic payloads including CAR constructs into primary human T cells and reported >90% tumor-cell clearance in lab assays. The team also reported high success designing antimicrobial peptides against WHO critical-priority pathogens. EDEN’s approach differs from standard CRISPR by targeting insertion of larger payloads; Basecamp filed a preprint and has not yet published peer-reviewed data. The disclosure underscores growing industry interest in generative AI for design of complex biological constructs.